- Home
- KPLT vs INKT Comparison
KPLT vs INKT Comparison
Compare KPLT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPLT | INKT |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 51.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KPLT | INKT |
|---|---|---|
| Price | $6.91 | $11.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.1M | 20.6K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $280,839,000.00 | N/A |
| Revenue This Year | $21.42 | N/A |
| Revenue Next Year | $15.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $5.08 | $4.56 |
| 52 Week High | $24.34 | $76.00 |
Technical Indicators
Market Signals| Indicator | KPLT | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 50.56 |
| Support Level | $6.24 | $11.33 |
| Resistance Level | $6.80 | $12.31 |
| Average True Range (ATR) | 0.57 | 0.72 |
| MACD | 0.22 | 0.07 |
| Stochastic Oscillator | 28.79 | 48.09 |
Price Performance
Historical ComparisonAbout KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.